In a groundbreaking development for patients with HPV15-positive first-line recurrent and/or metastatic head and neck cancer, a combination therapy of PDS0101 (Versamune HPV) and Keytruda (pembrolizumab) has demonstrated remarkable results, with a median overall survival exceeding three years. This significant finding stems from the VERSATILE-002 phase 2 clinical trial conducted by PDS Biotechnology Corporation, marking a pivotal moment in the realm of immunotherapy for head and neck squamous cell cancer.
The trial revealed that patients with a Combined Positive Score (CPS) of at least 1 experienced a median overall survival of 39.3 months when treated with the PDS0101-Keytruda combination. The treatment protocol involved administering PDS0101 subcutaneously alongside Keytruda via IV infusion for the initial four cycles, followed by maintenance with monotherapy Keytruda until disease progression or cycle 35, showcasing the potential for prolonged survival benefits.
Dr. Kirk Shepard, Chief Medical Officer of PDS Biotech, emphasized the enduring clinical impact of PDS0101, underscoring its promise in delivering favorable survival outcomes, as evidenced by previous studies such as the IMMUNOCERV and NCI-led trials. The simplicity of administering PDS0101 coupled with its encouraging efficacy signals a beacon of hope for HPV16-positive head and neck cancer patients, addressing a critical unmet medical need in the landscape of oncology.
The positive outcomes from the VERSATILE-002 trial position PDS Biotech as a frontrunner in addressing the escalating prevalence of HPV16-positive head and neck squamous cell carcinoma (HNSCC) in the US and Europe. As highlighted by Frank Bedu-Addo, President and CEO of PDS Biotech, the imperative for targeted therapies to combat the underlying cause of the disease is underscored by the urgent medical necessity, with a focus on enhancing patient survival prospects while ensuring treatment tolerability and continuity.
Notably, the tolerability profile of the PDS0101-Keytruda combination proved favorable, with no patients discontinuing the trial due to treatment-related adverse events. This safety profile, coupled with the robust efficacy data, positions the therapeutic duo as a promising avenue for healthcare providers seeking to optimize treatment outcomes for patients with head and neck cancer. The ongoing VERSATILE-002 trial, active across 23 global locations and estimated for completion in June 2025, signifies a continued dedication to advancing immunotherapeutic solutions in the oncology landscape.
Key Takeaways:
– The PDS0101-Keytruda combination demonstrates a median overall survival exceeding three years in HPV15-positive head and neck cancer patients.
– PDS Biotech’s VERSATILE-002 trial showcases the enduring clinical efficacy of PDS0101 in addressing the unmet medical needs of HPV16-positive HNSCC patients.
– The therapeutic duo offers a well-tolerated treatment option with no trial discontinuations due to adverse events, emphasizing its safety profile.
– The ongoing commitment to immunotherapeutic advancements in the VERSATILE-002 trial underscores a strategic focus on elevating patient survival outcomes in head and neck cancer.
Tags: immunotherapy, biotech
Read more on curetoday.com